- Page 1 and 2: Euro GTP Guidance EUROGTP Europea
- Page 3 and 4: Table of Contents PURPOSE AND SCOPE
- Page 5 and 6: A.5.1.4.1.2. Microbiological contro
- Page 7 and 8: B.3.1.2. Access to the processing f
- Page 9 and 10: D.2.1.2.2. Recovery ...............
- Page 11 and 12: F.1.1.2.Donor consent..............
- Page 13 and 14: PURPOSE AND SCOPE The European Good
- Page 15 and 16: SECTION A: GENERAL REQUIREMENTS A.1
- Page 17 and 18: a) Ensure that the tissues / cells
- Page 19 and 20: These responsibilities may be perfo
- Page 21 and 22: 3. This classification should be gu
- Page 23 and 24: A.2.1.3. Materials 1. Procurement m
- Page 25 and 26: 8. Drains should be of adequate siz
- Page 27: 11. Storage facilities must be prov
- Page 31 and 32: 2. When ‘in operation’ requirem
- Page 33 and 34: 4. Maintenance workshops should as
- Page 35 and 36: 5. A standardized written procedure
- Page 37 and 38: 1. A system to ensure that any dece
- Page 39 and 40: organ donation, the corpse does not
- Page 41 and 42: Explanation of costs involved and t
- Page 43 and 44: c) confirmed that all the informati
- Page 45 and 46: 4. The extra medical costs incurred
- Page 47 and 48: c. confirmed that all the informati
- Page 49 and 50: corticosteroids Provide details on
- Page 51 and 52: 3. A written report on the findings
- Page 53 and 54: a) Any person who stayed in Britain
- Page 55 and 56: 3. For any donation, the collection
- Page 57 and 58: not required. Retesting is also not
- Page 59 and 60: 2. Where tissues and cells of allog
- Page 61 and 62: l) Proof of consent for donation of
- Page 63 and 64: 4. It is recommended that the donor
- Page 65 and 66: A.4.1.2.3.2. Reconstruction of the
- Page 67 and 68: A.4.1.5.1. Primary packaging and la
- Page 69 and 70: according to the safety and preserv
- Page 71 and 72: 2. The report must also contain the
- Page 73 and 74: c) results of physical examination,
- Page 75 and 76: 2. A written procedure designed to
- Page 77 and 78: A.5.1.4. Quality Control 1. The eva
- Page 79 and 80:
5. Labels should be designed to adh
- Page 81 and 82:
6. Records must be legible and inde
- Page 83 and 84:
3. Traceability must be ensured fro
- Page 85 and 86:
6. Each tissue bank should establis
- Page 87 and 88:
With the growing global circulation
- Page 89 and 90:
13. The transport conditions should
- Page 91 and 92:
A.6.4. DOCUMENTATION AND RELEASE A.
- Page 93 and 94:
1. Member States shall take all nec
- Page 95 and 96:
f) Records are made, manually and/o
- Page 97 and 98:
4. Member States shall also ensure
- Page 99 and 100:
g) Review of all the critical devia
- Page 101 and 102:
3. Where tissue that has been relea
- Page 103 and 104:
e) Records are made, manually and/o
- Page 105 and 106:
g) Initials of the persons who veri
- Page 107 and 108:
2. A representative sample should b
- Page 109 and 110:
d) Related documents; e) Stages of
- Page 111 and 112:
f) Reference of the procedures invo
- Page 113 and 114:
g) Additional testing to be carried
- Page 115 and 116:
7. For cleaning and disinfection pr
- Page 117 and 118:
6. TEs shall provide copies of agre
- Page 119 and 120:
5. The procedure for notifying seri
- Page 121 and 122:
2. Seriousness might relate to pote
- Page 123 and 124:
B.1.1.3.2.4.Exclusion criteria 1. T
- Page 125 and 126:
B.1.1.3.2.4.1.3. Infections Persons
- Page 127 and 128:
performing staff. This includes due
- Page 129 and 130:
The eye must not be immersed in sol
- Page 131 and 132:
The package and the mode of transpo
- Page 133 and 134:
Additionally, antimicrobial effects
- Page 135 and 136:
B.3.1.4.2.1.2.Slit lamp evaluation
- Page 137 and 138:
B.3.1.6.2.1.1. Organ culture of cor
- Page 139 and 140:
Donor corneas with an endothelial c
- Page 141 and 142:
threatening for the recipient(s) or
- Page 143 and 144:
d) Placenta storage until earliest
- Page 145 and 146:
The methods for discarding donor ti
- Page 147 and 148:
C.3.1.7.2. Release See generic requ
- Page 149 and 150:
The use of skin allografts for chil
- Page 151 and 152:
D.2. RECOVERY D.2.1. ACTIVITIES D.2
- Page 153 and 154:
D.3. PROCESSING D.3.1. ACTIVITIES D
- Page 155 and 156:
2. With the bacteriological and myc
- Page 157 and 158:
D.3.1.5.1. Primary packaging and la
- Page 159 and 160:
a) Vitrification; b) Preservation i
- Page 161 and 162:
m) Bacterial or fungal endocarditis
- Page 163 and 164:
E.3. PROCESSING E.3.1. ACTIVITIES E
- Page 165 and 166:
GRADE 3 Normal valve leaflet; Posit
- Page 167 and 168:
Petechiae in otherwise perfect graf
- Page 169 and 170:
Damaged during dissection in the Ba
- Page 171 and 172:
E.3.1.4.1. Microbiological control
- Page 173 and 174:
cryopreservation the frozen tissues
- Page 175 and 176:
F.1.3.3.2.4. Exclusion criteria 1.
- Page 177 and 178:
F.2.1.1.2.2. Gowning Staff performi
- Page 179 and 180:
F.2.1.2.3.1.1 Femoral head donors P
- Page 181 and 182:
environmental temperatures, a tempe
- Page 183 and 184:
ethanol) to remove the chloroform e
- Page 185 and 186:
It is also necessary to mention the
- Page 187 and 188:
F.3.1.6.2.1. Preservation and stora
- Page 189 and 190:
j) Integrity of packaging material.
- Page 191 and 192:
CROSS CONTAMINATION: Contamination
- Page 193 and 194:
communicable disease, to death or l
- Page 195 and 196:
G.2. ACRONYMS ATMP Advance Therapy
- Page 197 and 198:
7. Recommendation (98) 2 on provisi
- Page 199 and 200:
G.4. TISSUE ESTABLISHMENT DOSSIER 1
- Page 201 and 202:
EUSTITE Deliverable 18 Inspection G
- Page 203 and 204:
How have the processing methods app
- Page 205 and 206:
Section D - Facilities EUSTITE Deli
- Page 207 and 208:
Section I - Quality System Please g
- Page 209 and 210:
GUIDE FOR AUDITING TISSUE ESTABLISH
- Page 211 and 212:
verification. Yes No N/A � Physio
- Page 213 and 214:
A.5. TRACEABILITY Is there an effec
- Page 215 and 216:
3. Risk assessments carried out for
- Page 217 and 218:
Is the label resistant to water? Ye
- Page 219 and 220:
Auditor Comments: A.9 RECORDS AND R
- Page 221 and 222:
2. Donor identity Is donor identifi
- Page 223 and 224:
6. Physical Examination Requirement
- Page 225 and 226:
Are serological tests performed on
- Page 227 and 228:
Auditor Comments: C.2 RETRIEVAL CON
- Page 229 and 230:
Yes No N/A Does the facility mainta
- Page 231 and 232:
PART D: TISSUE PROCESSING D.1 GENER
- Page 233 and 234:
effectiveness against the desired o
- Page 235 and 236:
D.2 EQUIPMENT SUITABILITY, STERILIT
- Page 237 and 238:
Is there evidence staff is regularl
- Page 239 and 240:
D.4 TRACEABILITY OF TISSUE THROUGH
- Page 241 and 242:
Sampling occurs at time critical po
- Page 243 and 244:
Are there: � SOP for release in p
- Page 245 and 246:
F.4 ADVERSE EVENT/REACTION MONITORI